One abnormal value or vomiting after oral glucose tolerance test in pregnancy: incidence and impact on maternal-fetal outcomes. 2023

Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.

To analyze pregnancy outcomes of women with one abnormal value (OAV) during oral glucose tolerance test (OGTT) or OGTT-intolerance, compared with gestational diabetes mellitus (GDM) and normal glucose tolerance (NGT) pregnant women, according to whether they received any health intervention or not. An observational retrospective study was designed including pregnant women who gave birth at Hospital del Mar, Barcelona (Spain) during December/2014-July/2018. Baseline characteristics, pregnancy outcomes and health interventions were obtained from a database collected previously for other study. Inclusion criteria were singleton pregnancies with OAV or OGTT-intolerants who gave birth at the Hospital. GDM screening followed a two-step approach: 50 g O'Sullivan test and 100 g 3-hour OGTT if the former was abnormal. From a total of 2,662 pregnancies, 326 (12.2%) had GDM, 87 OAV (3.3%), 65 OGTT intolerance (2.4%) and 2,184 were NGT women. First trimester HbA1c in both OAV and OGTT-intolerant women was significantly higher than in NGT group, and significantly lower than in GDM pregnants. No differences in obstetric outcomes were found between OGTT-intolerants and NGT/GDM groups. Treated OGTT-intolerants had greater gestational age at delivery than non-treated ones (weeks, 39.6 ± 1.2 vs 38.0 ± 4.0, respectively). In OAV women, significant differences were observed in newborns' birthweight (g, 3227.3 ± 500.8 vs 3351.1 ± 436.7, vs GDM) and gestational age at birth (weeks, 38.7 ± 1.8 vs 39.3 ± 1.9, vs NGT), but not in macrosomia/pre-eclampsia. No differences were found according to treatment in OAV. OAV and OGTT-intolerants account for a third of pregnant women referred to Diabetes Unit. Their rates of preterm birth, pre-eclampsia and macrosomia were not different from NGT or GDM women.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females
D005320 Fetal Macrosomia A condition of fetal overgrowth defined as BIRTH WEIGHT greater than 4,000 grams, regardless of gestational age. It is commonly seen in GESTATIONAL DIABETES; PROLONGED PREGNANCY; and pregnancies complicated by pre-existing diabetes mellitus. Macrosomia, Fetal,Fetal Macrosomias,Macrosomias, Fetal
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
January 1989, American journal of obstetrics and gynecology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
April 2022, American journal of perinatology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
August 1994, Clinical biochemistry,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
July 1989, Obstetrics and gynecology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
January 1989, Obstetrics and gynecology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
September 1989, American journal of obstetrics and gynecology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
September 1987, American journal of obstetrics and gynecology,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
October 2014, Ginekologia polska,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
August 2023, Diabetes research and clinical practice,
Humberto Navarro-Martinez, and Juana-Antonia Flores-Le Roux, and Gemma Llauradó, and Lucia Gortazar, and Antonio Payà, and Laura Mañé, and Juan Pedro-Botet, and David Benaiges
August 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
Copied contents to your clipboard!